Commercialization of Collaboration Products Sample Clauses

Commercialization of Collaboration Products. Commercialization of a Collaboration Product may not occur until the JSC agrees in writing that the Collaboration Product is ready for Commercialization. Furthermore, upon the commencement of the [***], whichever is occurs first, for any Collaboration Product, the Parties shall amend the respective Development and Commercialization Plan for such Collaboration Product in good faith by adding a Commercialization addendum that shall: [***]. The JSC shall amend each Commercialization addendum to the respective Development and Commercialization Plan at least [***], or more frequently if agreed to by the JSC.

Commercialization of Collaboration Products. Unless a Party has opted-out prior to such time, the Parties will share in all profits and losses arising from any Collaboration Product in the same ratios in which the Parties bore Development Costs for such Collaboration Program. In general, except for the Antibody Program, as set forth below, the Lead Party for Development will continue to act as the “Lead Commercialization Party” or “LCP” for such Collaboration Program. The LCP will conduct its activities in accordance with an agreed upon commercialization plan (the “Commercial Plan”) and budget (“Commercial Budget”) (with a [***] overage provision) for such countries. For each Antibody Product, following the filing for Regulatory Approval (i.e. an NDA or MAA, as applicable), GSK will assume the role of LCP for the Commercialization of each such Antibody Product, and will be responsible for booking all sales of such Antibody Product. GSK will be responsible for all Commercialization activities worldwide with respect to each Collaboration Product, except (a) for detailing conducted by Vir in the US Territory under the Co-Promotion Agreement, if agreed by the Parties, for so long as the Co-Promotion Agreement is in effect, and (b) in connection with sales in the WuXi Territory for Antibody Products arising or licensed to WuXi under the WuXi Agreement and directed to SARs-COV-2. GSK will be required to use commercially reasonable efforts to Commercialize each Collaboration Product in the US following regulatory approval in the US, in [***] following regulatory approval in the European Union, and the United Kingdom, following regulatory approval in the United Kingdom. Except in the case of an Opt-Out, for each Collaboration Product, Vir and GSK will share net profits and net losses, to be defined in the Definitive Collaboration Agreement from commercialization of any Collaboration Product worldwide.

Commercialization of Collaboration Products. GSK in its sole discretion will make all decisions regarding the commercialization and sales and marketing of Collaboration Products in the Territory and will book all sales of Collaboration Products. GSK will use Commercially Reasonable Efforts to commercialize Collaboration Products in all countries of the Territory.

Commercialization of Collaboration Products. Wyeth-Ayerst in its sole discretion will make all decisions regarding the commercialization and sales and marketing of Collaboration Products and will use Commercially Reasonable Efforts to commercialize Collaboration Products in those countries of the world where such Collaboration Products have received Regulatory Approval. The use of Commercially Reasonable Efforts by any Affiliate or sublicensee of Wyeth-Ayerst to commercialize Collaboration Products in a country shall satisfy Wyeth-Ayerst's obligation to use Commercially Reasonable Efforts to commercialize such Collaboration Product in such country.

Commercialization of Collaboration Products